Celldex Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.5M | $7.0M | $6.9M | $2.4M | $4.7M |
| Cost of revenue | $200,000 | $200,000 | $300,000 | $100,000 | $100,000 |
| Research and development | $245.1M | $163.6M | $118.0M | $82.3M | $53.3M |
| Operating income | -$287.4M | -$195.1M | -$154.5M | -$115.2M | -$71.2M |
| Pretax income | -$258.8M | -$157.9M | -$141.4M | -$112.3M | -$70.7M |
| Income tax expense | $0 | $0 | $0 | — | -$227,000 |
| Net income | -$258.8M | -$157.9M | -$141.4M | -$112.3M | -$70.5M |
| Balance Sheet | |||||
| Cash and equivalents | $28.9M | $28.4M | $34.8M | $29.4M | $39.1M |
| Current assets | $534.7M | $747.2M | $431.7M | $317.7M | $410.8M |
| Total assets | $583.0M | $792.3M | $465.6M | $352.7M | $444.7M |
| Current liabilities | $51.0M | $39.5M | $31.1M | $18.6M | $16.5M |
| Total liabilities | $55.8M | $45.3M | $36.5M | $26.5M | $25.2M |
| Stockholders' equity | $527.2M | $747.0M | $429.2M | $326.2M | $419.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$210.9M | -$157.8M | -$107.3M | -$103.7M | -$60.9M |
| Depreciation and amortization | $3.4M | $3.2M | $3.0M | $2.9M | $3.1M |
| Stock-based compensation | $36.2M | $34.2M | $23.9M | $15.6M | $9.0M |
| Capital expenditure | $2.7M | $1.9M | $1.8M | $1.8M | $1.2M |
| Free cash flow | -$213.7M | -$159.7M | -$109.1M | -$105.6M | -$62.2M |
| Impairments | — | — | — | — | $3.5M |
Shares outstanding 78.5M · Free float 92.4%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.